Filing Flows › CV Sciences (CVSI) › Q4 2025
CV Sciences (CVSI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
CV Sciences (CVSI) reported revenue of $3.3M for the fourth quarter 2025 (Q4 2025), -15% from a year earlier and +2% from the quarter before. Operating margin was -2.3%, net loss $206K (6.2% of revenue).
CV Sciences, Q4 2025: revenue $3.3M (-15% year over year), operating margin -2.3%, net loss $206K, operating cash flow −$354K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | +2% | -15% |
| Operating profit | −$75K | — | — |
| Net earnings | −$206K | — | — |
| Operating cash flow | −$354K | — | — |
What changed
Revenue was $3.3M in Q4 2025, down 15% year over year and up 2% from the previous quarter.
Gross margin was 50.5%, up 7.4 points from Q4 2024. Operating costs exceeded revenue by $75K, an operating margin of -2.3%. Operating expenses fell 25% while revenue fell 15%. The quarter ended with a net loss of $206K, narrower than the previous quarter's $382K loss. Net interest and other expense of $129K was the main reason.
Operating cash flow was −$354K. Non-cash charges added back $21K of depreciation and amortization and $123K of share-based compensation. Working capital and other items used $292K. Capital expenditures of $9K exceeded it, leaving free cash flow of −$363K.
Questions
What was CV Sciences' revenue in the fourth quarter 2025?
CV Sciences (CVSI) reported revenue of $3.3M for the fourth quarter 2025 (Q4 2025), -15% from a year earlier and +2% from the quarter before.
Was CV Sciences profitable in the fourth quarter 2025?
Operating loss was $75K (-2.3% of revenue) and net loss $206K.
Source: CV Sciences 10-K on SEC EDGAR.